Safety First

GAVIS® is focused on product safety and conduct comprehensive safety monitoring and evaluation throughout all stages of our product lifecycle. We are also committed to the safe and efficacious use of our products and provide disclosures on the risk/benefits of our products. If you experience any unanticipated side effects or have a complaint about our product, please contact GAVIS at 908-603-6080.


A generic drug is identical – or bioequivalent – to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Although generic drugs are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price. According to the Congressional Budget Office, generic drugs save consumers an estimated $8 to $10 billion a year at retail pharmacies. Even more billions are saved when hospitals use generics.


Drug companies must submit an abbreviated new drug application (ANDA) for approval to market a generic product. The Drug Price Competition and Patent Term Restoration Act of 1984, more commonly known as the Hatch-Waxman Act, made ANDAs possible by creating a compromise in the drug industry. Generic drug companies gained greater access to the market for prescription drugs, and innovator companies gained restoration of patent life of their products lost during FDA’s approval process.


New drugs, like other new products, are developed under patent protection. The patent protects the investment in the drug’s development by giving the company the sole right to sell the drug while the patent is in effect. When patents or other periods of exclusivity expire, manufacturers can apply to the FDA to sell generic versions. The ANDA process does not require the drug sponsor to repeat costly animal and clinical research on ingredients or dosage forms already approved for safety and effectiveness. This applies to drugs first marketed after 1962.
Health professionals and consumers can be assured that FDA approved generic drugs have met the same rigid standards as the innovator drug. To gain FDA approval, a generic drug must:

  • contain the same active ingredients as the innovator drug (inactive ingredients may vary)
  • be identical in strength, dosage form, and route of administration
  • have the same use indications
  • be bioequivalent
  • meet the same batch requirements for identity, strength, purity, and quality
  • be manufactured under the same strict standards of FDA’s good manufacturing practice regulations required for innovator products

Educational Resources: Generic Drugs
These educational resources provide information on buying and using generic drugs. They are intended for use by educators, health care professionals, and consumers.

Most materials are available in PDF format for immediate downloading or printing. Some materials may be ordered in print at no cost. Send requests for printed materials to or call

1-888-INFO-FDA or visit
U.S. Food and Drug Administration,

10903 New Hampshire Avenue ,

Silver Spring, MD 20993


1-888-INFO-FDA (1-888-463-6332)
U.S. Consumer Reports